lupus
FDA approves AZ’s anifrolumab, ending 10-year lupus drug drought
Phil Taylor
anifrolumab, AstraZeneca, fda, lupus, lupus nephritis, regulatory approval, Saphnelo
0 Comment
Merck takes on Lilly/Nektar in IL-2 with $1.85bn Pandion buy
Phil Taylor
autoimmune disease, lupus, M&A, Merck & Co, Pandion Therapeutics, ulcerative colitis
0 Comment
GSK’s Benlysta claims first FDA okay for lupus kidney damage
Phil Taylor
Benlysta, fda, GlaxoSmithKline, lupus, lupus nephritis
0 Comment
PREDiCT: Autoimmune Disease Modeling Summit
jenna.warren@hansonwade.com
autoimmune, Diabetes, IBD, lupus, Sclerosis
0 Comment
Deploy Advanced Models to Enhance Your Confidence & Und
AZ fleshes out positive trial of revitalised lupus drug anifrolumab
Phil Taylor
AstraZeneca, autoimmune disease, Gazyvaro, lupus, lupus nephritis, Roche
0 Comment
Gilead says arthritis drug filgotinib fails in follow-up use trials
Phil Taylor
autoimmune disease, filgotinib, Galapagos, Gilead Sciences, JAK inhibitor, lupus
0 Comment
Could phase 3 trial win save AZ’s troubled Lupus drug?
Richard Staines
AstraZeneca, GlaxoSmithKline, inflammatory diseases, lupus
0 Comment